Pharmacokinetics and safety of escalating single and repeat oral doses of GW420867X, a novel non-nucleoside reverse transcriptase inhibitor

European Journal of Clinical Pharmacology

Volumn 56, Issue 11, 2001, Pages 805-811

  Moore, K H P ^a,c   Cass, L M ^a   Dallow, N ^a   Hardman, T C ^a   Jones, A ^a   Boyce, M ^b   Prince, W T ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b CENTRAL MIDDLESEX HOSPITAL   (United Kingdom)

^c GLAXOSMITHKLINE   (United States)

Author keywords

Human immunodeficiency virus (HIV); Non nucleoside reverse transcriptase inhibitor (NNRTI); Pharmacokinetics

Indexed keywords

2 ETHYL 7 FLUORO 1,2,3,4 TETRAHYDRO 3 OXO 1 QUINOXALINECARBOXYLIC ACID ISOPROPYL ESTER; QUINOXALINE DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ANALYSIS OF VARIANCE; AREA UNDER THE CURVE; ARTICLE; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; HALF LIFE TIME; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTESTINE ABSORPTION; MALE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADULT; ANALYSIS OF VARIANCE; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; HALF-LIFE; HUMANS; INTESTINAL ABSORPTION; MALE; MIDDLE AGED; QUINOXALINES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0035230425     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280000224     Document Type: Article

References (19)

1. Bright DC (1999) Antiretroviral therapy for HIV infection: a review of current medications and therapies. J Am Opt Assoc 70: 355-383
2. De Clercq E (1999) Perspectives of non-nucleoside reverse transeriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Farmaco 54: 26-45
3. Brinkman K, Smeitink JA, Romijn JA, Reiss P (1999) Mitochondrial toxicity induced by nucleoside-analogue reversetranscriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 354: 1112-1115
4. Schooley RT (1999) Longer-term immunologic effects and side effects of successful antiretroviral therapy. Clin Infect Dis 29: 12-18
5. Vigouroux C, Gharakhanian S, Salhi Y, Nguyen TH, Chevenne D, Capeau J, Rozenbaum W (1999) Diabetes, insulin resistance and dyslipidaemia in lipodystrophic HIV-infected patients on highly active antiretroviral therapy (HAART). Diab Mctab 25: 225-232
6. Bulzurini J, Karlsson A, Perez PM, Camarasa MJ, Tarpley WG, De Clercq E (1993) Treatment of human immunodeficiency virus type I (HIV-1)-infected cells with combination of HIV-1-specific inhibitors results in a different resistance pattern than does treatment with single-drug therapy. J Virol 67: 5353-5359
7. Carosi G, Toni C, Palvarini L, Roldan EQ (1999) HIV-1 phannacoresistance: clinical and therapeutic implications. EQ J Biol Regul Homeost Agents 13: 163-171
8. De Clercq E (1993) HIV-1-specific RT inhibitors: highly selective inhibitors of human immunodeficiency virus type-1 that are targeted at the viral reverse transeriptase. Med Res Rev 13: 229-258
9. Kleim JP, Burt V, Maguire MF, Mutch P, Hazen RJ, St. Clair M (1999) GW420867X: a novel quinoxaline-class NNRTI of HIV-1 with improved antiretroviral properties in the presence of human serum and its components (abstract 599). In: The 6th Conference on Retroviruses and Opportunistic Infections Program and s: Foundation for Retrovirology and Human Health. National Institutes of Allergy and Infectious Diseases, and the Center for Disease Control and Prevention. Alexandria, VA, pp 120
10. Prince W, Moore K, Cass L, Dallow N, Jones A, Kleim JP, Mutch P, St Clair M (1999) GW420867X. A new non-nucleoside reverse transcriptor inhibitor (NNRTI) - initial Phase I evaluation (abstract 601). In: The 6th Conference on Retroviruses and Opportunistic Infections Program and s: Foundation for Retrovirology and Human Health, National Institutes of Allergy and Infectious Diseases, and the Center for Disease Control and Prevention, Alexandria, VA, pp 120
11. Koch GG (1972) The use of non-parametric methods in the statistical analysis of the two periods change-over design. Biometrics 28: 577-588
12. Gough K, Hutchinson M, Keene ON, Byrom B, Ellis S, Lacey LF, McKellar J (1995) Assessment of dose proportionality: report from statisticians in the pharmaceutical industry/pharmacokinetics UK Joint Working Party. Drug Info J 29: 1039-1048
13. Midha KK, Ormsby ED, Hubbard JW, McKay G, Hawes EM, Gavalas L, McGilveray IJ (1993) Logarithmic transformation in bioequivalence: application with two formulations of perphenazine. J Pharm Sci 82: 138-144
14. Merry C, Barry MG, Mulcahy F, Ryan M, Tjia JF, Halifax KL, Breckenridge AM, Back DJ (1998) The pharmacokinetics of combination therapy with nelfinavir plus nevirapine. AIDS 12: 1163-1167
15. Harris M, Herman ED, Caret BJ, Carlson GF, Betts DH (1998) Pharmacokinetic drug-drug interaction study of delavirdine and indinavir in healthy volunteers. J Acquir Immune Defic Syndr Hum Retrovirol 18: 252-259
16. Fiske WI, Benedek S, White S, Pepperess K, Joseph J, Kornhauser D (1998) Pharmacokinetic evaluation of efavirnez and nelfinavir mesylate in healthy volunteers (abstract 349). In: The 5th Conference on Retroviruses and Opportunistic Infections Program and s: Foundation for Retrovirology and Human Health. National Institutes of Allergy and Infectious Diseases, and the Center for Disease Control and Prevention. Alexandria. VA, p 144
17. Hayashi S, Jayesekera D, Jayewardene A, Shah A, The-vanayagam L, Aweeka F (1999) Altered pharmacokinetics of indinuvir by a novel non-nucleoside reverse transcriptase inhibitor (BAY-097): a pharmacokinetic evaluation in HIV-positive patients. J Clin Pharmacol 39: 1085-1093
18. Drusano GI, Moore KHP, Prince W, Kleim JP, McDade H, Bye A (1999) Dose evaluation for GW420867X using population pharmacokinetic (PK) modeling and Monte Carlo simulation (abstract 1200). In: s of 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, p 35
19. Wood R, Arasteh K, Muller M, Cass L, Moore KHP, Dallow N, Jones A, Burt V, Kleim JP, Prince W (1999) Preliminary tolerability, pharmacokinetics (PK) and initial effect on plasma HIV-1 RNA following administration of GW420867X once-daily (50 ing, 100 mg and 200 mg) for 28 days to patients infected with HIV-1 (abstract 493). In: 7th European Conference on Clinical Aspects and Treatment of HIV Infection, European AIDS Clinical Society, Germany, p 100